BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kazandjian D, Mo CC, Landgren O, Richardson PG. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol 2020;191:692-703. [PMID: 32501533 DOI: 10.1111/bjh.16764] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 McCaughan GJ, Gandolfi S, Moore JJ, Richardson PG. Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol 2022. [PMID: 35796524 DOI: 10.1111/bjh.18295] [Reference Citation Analysis]
2 Hernández-Rivas JÁ, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res 2022;10:1. [PMID: 35000618 DOI: 10.1186/s40364-021-00344-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Destefano CB, Gibson SJ, Sperling AS, Richardson PG, Ghobrial I, Mo CC. The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Aksenova AY, Zhuk AS, Lada AG, Zotova IV, Stepchenkova EI, Kostroma II, Gritsaev SV, Pavlov YI. Genome Instability in Multiple Myeloma: Facts and Factors. Cancers (Basel) 2021;13:5949. [PMID: 34885058 DOI: 10.3390/cancers13235949] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Morabito F, Tripepi G, Martino EA, Vigna E, Mendicino F, Morabito L, Todoerti K, Al-Janazreh H, D'Arrigo G, Canale FA, Cutrona G, Neri A, Martino M, Gentile M. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Drug Des Devel Ther 2021;15:2969-78. [PMID: 34262262 DOI: 10.2147/DDDT.S295215] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Jonsdottir G, Björkholm M, Turesson I, Hultcrantz M, Diamond B, Porwit A, Landgren O, Kristinsson SY. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. Eur J Haematol 2021;107:275-82. [PMID: 33966293 DOI: 10.1111/ejh.13650] [Reference Citation Analysis]
7 Schjesvold F, Oriol A. Current and Novel Alkylators in Multiple Myeloma. Cancers (Basel) 2021;13:2465. [PMID: 34070213 DOI: 10.3390/cancers13102465] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Ebraheem MS, Seow H, Balitsky AK, Pond GR, Wildes TM, Sivapathasundaram B, Sussman J, Mian H. Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clin Lymphoma Myeloma Leuk 2021;21:e714-21. [PMID: 34099429 DOI: 10.1016/j.clml.2021.05.002] [Reference Citation Analysis]
9 Poczta A, Rogalska A, Marczak A. Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches. J Clin Med 2021;10:1841. [PMID: 33922721 DOI: 10.3390/jcm10091841] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
10 Nadeem O, Richardson PG. The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. Br J Haematol 2021;193:213-5. [PMID: 33748954 DOI: 10.1111/bjh.17407] [Reference Citation Analysis]
11 Matsuzaki S, Matsuzaki S, Chang EJ, Yasukawa M, Roman LD, Matsuo K. Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature. Gynecol Oncol 2021;161:70-7. [PMID: 33419612 DOI: 10.1016/j.ygyno.2020.12.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]